REG - Genedrive PLC - Equity Fundraise

GenedriveAnnouncement

27/03/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250327:nRSa5641Ca&default-theme=true

RNS Number : 5641C  Genedrive PLC  27 March 2025

 

THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS
STATES, TERRITORIES AND POSSESSIONS ("UNITED STATES"), AUSTRALIA, CANADA,
JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN
WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY
APPLICABLE LAW.

 

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE
SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS
DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF
MAR.

 

genedrive plc

("genedrive" or the "Company")

 

Equity Fundraise

 

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company
announces that it has conditionally raised gross proceeds of £1.0 million by
means of a subscription (the "Subscription") for 66,666,666 new ordinary
shares of 1.5 pence each in the capital of the Company ("Ordinary Shares") by
the market making arm of Peel Hunt LLP  (the "Subscription Shares") at a
price of 1.5 pence per new Ordinary Share (the "Issue Price").

 

The Issue Price represents a discount of approximately 17.8% to the closing
mid-market price for genedrive shares on 26 March 2025.

 

Use of proceeds

The net proceeds from the Subscription will provide genedrive with additional
working capital as it actively pursues a broad range of growing commercial
opportunities in the UK and internationally at the present time, including
both commercial sales and potential non-dilutive grant income.  CE-IVD
certification for genedrive's CYP2C19 test, which is on track for April 2025,
will also enable in-country registration and subsequently sales of the test to
commence outside of the UK and genedrive is particularly encouraged by
opportunities presented in the Middle East region, where it has focused
significant efforts and expenditure to understand market access and
reimbursement routes as well as identification of primary target hospitals,
opinion leaders and healthcare organisations and will update further in due
course as opportunities are converted as appropriate.  The Subscription
provides the Company with an extended cash runway to seek to close a number of
the commercial and other opportunities in front of it and further drive
shareholder value.  The Board will continue to assess longer term financing
options in the meantime.

 

RetailBook Offer

The Company has separately engaged RetailBook to undertake a RetailBook Offer
of the RetailBook Shares at the Issue Price to existing retail investors
through the RetailBook platform alongside the Subscription.  The RetailBook
Offer is for up to 16,666,666 new Ordinary Shares (the "RetailBook Shares"),
raising gross proceeds of up to approximately £250,000 at the Issue Price.
The RetailBook Offer is not being underwritten.   A separate announcement
will be made shortly by the Company regarding the RetailBook Offer and its
terms and conditions.

 

Related Party Transaction

Peel Hunt LLP is a related party of the Company pursuant to the AIM Rules so
its participation in the Subscription (including the commission payable) is a
related party transaction for the purposes of AIM Rule 13.  The Directors
consider, having consulted with the Company's nominated adviser, Peel Hunt
LLP, whose Nominated Adviser function is independent of its market making arm,
confirms that the terms of the participation in the Subscription by Peel Hunt
LLP (including the commission payable) are fair and reasonable insofar as
Shareholders are concerned.

 

Further information on the Subscription

Peel Hunt LLP is charging an industry standard commission on the value of the
Subscription Shares.

 

Interim results

genedrive has today issued its unaudited interim results for the period ended
31 December 2024.

 

Admission

The Company has applied for the Subscription Shares and the maximum number of
RetailBook Shares that may be subscribed for to be admitted to trading on AIM
("Admission") by 8.00 a.m. on or around 3 April 2025.

 

The Subscription Shares and RetailBook Shares will, when issued, be credited
as fully paid and will rank pari passu in all respects with the existing
Ordinary Shares of the Company including the right to receive all dividends or
other distributions made, paid or declared in respect of such shares after
Admission.

 

The person responsible for arranging release of this announcement on behalf of
the Company is Russ Shaw, CFO.

 

For further information, please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                        +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com (http://www.genedriveplc.com)
).

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEASDXAAKSEFA